{
    "nct_id": "NCT06765707",
    "official_title": "Symptom Monitoring Using Patient-Reported Outcomes to Optimize Medication Use",
    "inclusion_criteria": "* Cisgender women assigned female at birth\n* Age 18 years or older\n* Stage 1-3 hormone receptor-positive breast cancer\n\n  1. Premenopausal patients being treated with GNRH agonist/antagonist to induce menopause are eligible\n  2. Patients who received treatment with CDK 4/6 inhibitors are eligible\n* Recommended to continue AET for â‰¥2 additional years after enrollment\n* Low adherence defined as prescription fills with a proportion of days covered (PDC) of <80%, examined over all fills during the 2 years prior to date of eligibility review since the first AET prescription/data of AET start OR unable to calculate adherence\n* Verbal fluency in English or Spanish\n* Ability to understand informed consent and the willingness to sign it\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Unable to verbalize comprehension of study or impaired decision-making\n* Known distant metastatic disease\n* Not receiving breast cancer care or AET prescription from provider at participating site\n* Evidence that an oncology provider discontinued their AET\n* Pregnant or trying to get pregnant\n* Facility-administered medications (i.e., nursing home, home healthcare agency)",
    "miscellaneous_criteria": ""
}